UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/599,793	03/23/2007	Marike Joanna Bernadette Molenaar	069818-3600	4654
	7590 03/30/201 LARDNER LLP	EXAMINER		
SUITE 500			GREENE, IVAN A	
3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1619	
			MAIL DATE	DELIVERY MODE
			03/30/2010	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No. Applicant(s)					
Office Action Summary	10/599,793	MOLENAAR, MARIKE JOANNA BERNADETTE				
omoo nodon odnimary	Examiner	Art Unit				
	IVAN GREENE	1619				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be time ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	Lely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 22 De	ecember 2009.					
2a)⊠ This action is <b>FINAL</b> . 2b)□ This	This action is <b>FINAL</b> . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ☐ Claim(s) 17,18,21-27 and 29-49 is/are pending 4a) Of the above claim(s) 32-48 is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 17,18,21-27,29-31 and 49 is/are rejection is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	rn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the other contraction. The oath or declaration is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)	_					
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO/SB/08)         Paper No(s)/Mail Date     </li> </ol>	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6) Other:	te				

#### **DETAILED ACTION**

#### Status of the claims

Claims 17, 18, 21-27 and 29-49 are currently pending. Claims 1-16, 19, 20 and 28 have been canceled by applicant. Claims 32-48 have been withdrawn based upon a restriction discussed in the first office action on the merits dated 06/23/2009. Claims 17, 18, 21-27, 29-31 and 49 are currently being examined on the merits.

All rejections and/or objections not explicitly maintained in the instant office action have been withdrawn per Applicants' claim amendments and/or persuasive arguments.

## Amendments to the specification

The amendments to the specification (including the replacement abstract) have been checked by the examiner and introduce no new matter.

#### **Priority**

The U.S. effective filing date has been determined to be 04/08/2005, the filing date of the document PCT/NL05/00269. The foreign priority date has been determined to be 04/09/2004, the filing date of document EP 04076132.2.

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/599,793 Page 3

Art Unit: 1619

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 1. Claims 17, 18, 21-27, 29-31 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over HAGEMAN (US 2002/0142025) and FUCHS (US 6,605,310) in view of SHIBUYA (US 5,576,303) and TANEYA (US 4,146,456).

## **Applicant Claims**

Applicant claims a liquid complete nutritional composition suitable for feeding cachectic patients and having an energy density of at least 1.45 kcal/mL comprising: (a) a carbohydrate fraction in an amount of 17 to 27 g/100 mL comprising 15-45 wt% of trehalose; (b) a protein fraction comprising intact protein fraction in an amount of 8.5 to 10 g/100 mL; and (c) a lipid fraction; and wherein at least 70 wt. % of the protein fraction is obtained from demineralized milk, and wherein the intact protein comprises between 25 and 37 wt.% of whey proteins. Applicant further claims the protein fraction (b) comprises at least 1.0 wt. % of cystine residues. Applicant further claims the liquid composition further comprises 0.5 to 6 grams of fiber per 100 mL. Applicant further claims the protein fraction (b) comprises at least 8.6 wt. % of lysine residues, at least 2.5 wt. % of methionine residues, and at least 0.5 wt. % of cystine residues. Applicant further claims the liquid composition comprises 60-75 wt.% casein. Applicant further claims the lipid fraction is in an amount of 5.0 to 7.0 g/100 mL. Applicant further claims the carbohydrate fraction (c) comprises 18 to 23.5 g/100 mL. Applicant further claims

the liquid composition having a viscosity below 50 mPa·s at a shear rate of 100 s<sup>-1</sup> and a temperature of 20 °C. Applicant further claims a powder, which upon reconstitution with water, provides the liquid complete nutritional composition, as described above.

## **Determination of the scope**

# and content of the prior art (MPEP 2141.01)

HAGEMAN teaches an enteral food composition for clinical or dietary use comprising carbohydrates, proteins (abstract). HAGEMAN further teaches the compositions contain carbohydrates, proteins and fats ([0032]). HAGEMAN further teaches proteins may be used as amino acid sources, provided that the desired amino acids become readily available by digestion ([0025]). HAGEMAN further teaches cystine-rich proteins include dairy whey proteins and specific proteins thereof ([0025]). HAGEMAN further teaches methionine-rich proteins include casein, casinates and casein hydrolysates ([0025]). HAGEMAN further teaches the composition should comprise sufficient levels of essential amino acids such as lysine ([0031]). HAGEMAN further teaches the carbohydrates can comprise mono-, di-, oligo-, and polysaccharides, such as glucose, fructose, maltose, sucrose, fructo-, galacto- and especially glucooligosaccharides, starch, starch hydrolysates and the like ([0032]). HAGEMAN further teaches the proteinaceous material is in the form of proteins or peptides, especially in the form of intact proteins ([0032]). HAGEMAN further teaches Example 4 ([0050], [0051]) with an energy content of 1.50 kcal/mL; a protein content (casein/whey; 80/20) of 8.2 g/100 mL; a carbohydrate content of 16.5 g/100 mL; a fat content of 5.5 g/100

mL; and a fiber content of 0.4 g/100 mL. HAGEMAN further teaches complete enteral tube feeding composition in a spray-dried powdered form (Example 2, claim 9).

Regarding the range of protein as currently claimed: HAGEMAN further teaches Example 4 ([0050], [0051]) with an energy content of 1.50 kcal/mL; a protein content (casein/whey; 80/20) of 8.2 g/100 mL; a carbohydrate content of 16.5 g/100 mL; a fat content of 5.5 g/100 mL; and a fiber content of 0.4 g/100 mL ([0051]). HAGEMAN does not expressly teach a preferred general range of protein content for the nutritional drink composition. However FUCHS teaches a higher protein content liquid oral supplement and provides motivation to increase the protein content of a liquid oral supplement. FUCHS teaches their liquid oral supplement is designed for elderly individuals that may be malnourished and persons suffering from or recovering from a diseased state (3:10-14). FUCHS further teaches their product includes a protein source, a fat source, a carbohydrate source, and a source of vitamins and minerals (3:20-22). FUCHS further teaches the protein source provides at least 15% of the total caloric content of the supplement and further teaches the embodiment wherein the protein content is 90 grams per liter (or 9 grams per 100 mL).

# Ascertainment of the difference between the prior art and the claims (MPEP 2141.02)

The difference between the rejected claims and the teachings of HAGEMAN/FUCHS is that HAGEMAN/FUCHS does not expressly teach the non-reducing sugar trehalose or demineralized milk proteins. The deficiency in the non-

Art Unit: 1619

reducing sugar trehalose is cured by the teachings of SHIBUYA. The deficiency in the demineralized milk proteins is cured by the teachings of TANEYA.

SHIBUYA teaches the present invention relates to a energy-supplementing saccharide source and uses thereof, more particularly, to an enengy-supplementing saccharide source essentially consisting of trehalose (1:14-17). SHIBUYA further teaches reducing saccharides such as glucose and fructose have been used for a long time as energy supplement saccharide sources (1:24-26). SHIBUYA further teaches the reducing saccharides have a relatively-poor storage stability because of their reducing power, and generally become more unstable in coexistence with other nutritives such as amino acids and vitamins (1:26-30). SHIBUYA further teaches an energy-supplementing saccharide source essentially consisting of a non-reducing saccharide source, such as xylitol, sorbitol, maltitol, lactitol, sucrose or trehalose has been in great demand (1:31-34).

TANEYA teaches demineralized cow's milk and an apparatus and method for producing demineralized cow's milk (abstract). TANEYA further teaches in the production of cow's milk powder it is desirable for the product, in its composition, to resemble human milk (1:18-19). TANEYA further teaches the content of minerals in milk used as a material of powdered milk is higher as compared to human milk and accordingly it is required to demineralize it in the production of infant milk powder (20-24).

Regarding the specific amounts of the recited carbohydrates, proteins, lipids and fiber it would have been obvious to the skilled artisan to produce a composition with the

proper amounts of said ingredients such that the patient's nutritional needs would have been met. The amounts of carbohydrates, proteins, lipids and fiber in the composition clearly would have been a result effective parameter that a person of ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ and reasonably would expect success. It would have been customary for a skilled artisan to determine the optimal amount of each ingredient to add in order to best meet the nutritional requirements of the intended patient's. Thus, in the absence of some demonstration of unexpected results from the claimed parameters, this optimization of ingredients would have been obvious at the time of Applicant's claimed invention.

Regarding the viscosity, where the claimed prior art products are substantially identical in structure or composition or are produced by identical or substantially identical processes a prima facie case of either anticipation or obviousness has been established. Absent evidence to the contrary the prior art composition must posses the claimed viscosity since it is substantially identical to the claimed composition. See MPEP 2112.01.

# Finding of prima facie obviousness

# Rationale and Motivation (MPEP 2142-2143)

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to combine FUCHS with HAGEMAN and produce the instantly claimed invention because FUCHS and HAGEMAN each teach similar liquid nutritional compositions. One skilled in the art would have been motivated to

combine FUCHS with HAGEMAN because it is generally considered to be prima facie obvious to combine compositions, each of which is taught by the prior art to be useful for the same purpose, in order to form a composition that is to be used for an identical purpose. The motivation for combining them flows from their having been used individually in the prior art, and from the being recognized in the prior art as useful for the same purpose. As shown by the recited teachings, instant claims are no more than the combination of conventional components of liquid nutritional compositions. It therefore follows that the instant claims define prima facie obvious subject matter. Cf. In re Kerkhoven, 626 F.2d 848, 205 USPQ 1069 (CCPA 1980).

Page 8

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to combine SHIBUYA with HAGEMAN/FUCHS and produce the instantly claimed invention because HAGEMAN/FUCHS teaches a nutritional composition comprising a milk product and SHIBUYA teaches an improved milk product. One of ordinary skill in the art would have been motivated to combine SHIBUYA with HAGEMAN/FUCHS because the demineralized milk, taught by SHIBUYA, would have provided a milk product which resembles human milk and would have been suitable for infants.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to combine TANEYA with HAGEMAN/FUCHS and produce the instantly claimed invention because HAGEMAN/FUCHS teaches a nutritional composition comprising a carbohydrate product and TANEYA teaches an improved carbohydrate product. One of ordinary skill in the art would have been

motivated to combine TANEYA with HAGEMAN/FUCHS because the use of trehalose, a non-reducing sugar, would have improved the stability of the product.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

#### **Response to Arguments:**

Applicant's arguments filed 12/22/2009 have been fully considered but they are not persuasive.

Applicant's arguments with respect to the protein content have been considered but are moot in view of the new ground(s) of rejection. However the examiner notes that Applicant's argument that "the prior art products contained a level of intact protein typically well below 8%, because attempts at higher concentrations are wrought with problems such as precipitation [...]" appears to indicate that the instantly claimed invention requires the protein be solubilized in the liquid. It is the examiners position that the claim(s) as currently recited are not limited to "solubilized protein."

Applicant's arguments regarding the viscosity have been considered, however, the examiner points out that this is a limitation that is not currently claimed. Thus, in

response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., viscosity) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

#### Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The following US patent documents are cited for applicant's consideration: TRIMBO (US 5,728,678); TROUP (US 2004/0087490); MARK (US 6,200,950); JOST (US 5,683,984); BJORKSTORM (US 2003/0118713); LIEBRECHT (US 5,641,531); DELAHANTY (US 2005/0129835); MONTE (US 6,423,354); and BATCHELDER (5,223,107).

Claims 17, 18, 21-27, 29-31 and 49 have been examined on the merits. Claims 17, 18, 21-27, 29-31 and 49 are rejected under 35 U.S.C. 103(a). No claims allowed at this time.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Art Unit: 1619

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to IVAN GREENE whose telephone number is (571)270-5868. The examiner can normally be reached on Monday through Thursday 7AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bonnie Eyler can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/599,793 Page 12

Art Unit: 1619

IVAN GREENE	/YVONNE L. EYLER/
Examiner, Art Unit 1619	Supervisory Patent Examiner, Art Unit
	1619